SAMPLES:
- 1-8) MMN patients: 09-2582, 09-299, 09-1218, 09-1461, 09-292, 09-190, 09-254, 09-1804 (dil. 1/10)
- 9) MS 163 (dil. 1/10)
- 10) MS 402 (dil.1/10)
- 11) MS 405 (dil.1/10)
- 12) MS 406 (dil.1/10)
- 13) MS 158 (dil.1/50)
- 14) MS 163 (dil. 1/50)
- 15) MS 247 (dil.1/50)
- 16) MS 307 (dil.1/50)
- 17) MS 316 (dil.1/50)
- 18) MS 406 (dil.1/50)
- 19) MS 158 (dil.1/30)
- 20) MS 163 (dil.1/30)
PROCEDURE
- Patient’s sera diluted 1/10 (or 1/30 or 1 /50) in PBS-Tween 0,2% (LCR 1/5) –> add 30 microl to each reaction field in the reagent tray: place the biochip slides on them and incubate for 30 min at RT
- Rinse the biochips with a flush of PBS-Tween 0,2% and immerse them in a cuvette containing PBS-Tween 0,2% for 5 minutes.
- Add 25 microL of the fluorescein-labelled secondary antibody (kit) in each reaction field: place the biochip slides on them and incubate for 30 min at RT
- Rinse the biochips with a flush of PBS-Tween 0,2% and immerse them in a cuvette containing PBS-Tween 0,2% for 5 minutes.
- Mount with the mounting medium from the kit
RESULT
- 1-8) MMN patients: 09-2582, 09-299, 09-1218, 09-1461, 09-292, 09-190, 09-254, 09-1804 (dil. 1/10): todas las muestras –
- 9) MS 163 (dil. 1/10): +
- 10) MS 402 (dil.1/10): –
- 11) MS 405 (dil.1/10): –
- 12) MS 406 (dil.1/10): –
- 13) MS 158 (dil.1/50): +
- 14) MS 163 (dil. 1/50): + (weak)
- 15) MS 247 (dil.1/50): –
- 16) MS 307 (dil.1/50): + +
- 17) MS 316 (dil.1/50): + +
- 18) MS 406 (dil.1/50): –
- 19) MS 158 (dil.1/30): + +
- 20) MS 163 (dil.1/30): + (weak)